Publications by authors named "J Birt"
Introduction: Some retrospective data sources, such as electronic health records in the USA, report composite outcome measures not fully validated in psoriatic arthritis (PsA). However, they often contain global assessments, such as a Physician Global Assessment (PhGA) and Patient Global Assessment (PatGA), along with patient-reported pain scores, which individually are considered validated in PsA. This research described the performance characteristics of a 3-item global assessment and pain (GAP) composite endpoint using data from the ixekizumab phase 3 PsA clinical trial program.
View Article and Find Full Text PDFBackground: Prior work showed that patients from the CorEvitas Psoriasis Registry who had previously failed a prior biologic and then initiated ixekizumab demonstrated improvements in disease severity and patient-reported outcomes after 6 months. However, newer therapies such as interleukin-23 inhibitors (IL-23i) were not considered. Here, with more recent data including IL-23i, 6-month effectiveness of ixekizumab following a switch from any biologic was assessed as well as whether 6-month effectiveness of ixekizumab was impacted by prior biologic class.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to describe the characteristics and clinical status of patients with psoriatic arthritis (PsA) who are being treated with ixekizumab, a medication used for this condition.
- Data was collected through a survey involving 68 rheumatologists and 275 patients, focusing on demographics, disease severity, treatment satisfaction, and symptom burden before and after starting ixekizumab.
- Results showed significant improvements in clinical features such as pain, fatigue, and joint counts after starting ixekizumab, indicating its effectiveness in real-world settings, supporting findings from clinical trials.
Introduction: A new, citrate-free ixekizumab formulation, which is bioequivalent to the original formulation, was associated with significant reduction in injection site pain. This study evaluates patient satisfaction with the first injection experience of citrate-free ixekizumab in a real-world setting.
Methods: A non-interventional, observational, web-based survey of adults (≥ 18 years) with psoriasis, psoriatic arthritis, or axial spondyloarthritis was conducted between August 2022 and March 2023.